The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 21: 3036 - 3039

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.21.012

Clinical Research

Effects of metoprolol succinate on acute stage pacing threshold and amplitude of intracardiac electrical signal in a leadless pacemaker

  • Kaidi JING ,
  • Cheng LI ,
  • Xiao MA ,
  • Shubin JIANG ,
  • Lan. LI
Expand
  • The Fourth Clinical Medical College of Xinjiang Medical University，Urumqi 830000，Xinjiang，China

Received date: 2024-05-15

  Online published: 2024-11-19

Fold

Abstract

Objective To investigate the effects of metoprolol succinate sustained-release tablets on acute phase ventricular pacing threshold and intracardiac electrical signal amplitude in a leadless pacemaker （Micra）. Methods A total of 100 patients implanted with a leadless pacemaker were selected and divided into a study group （n = 43） and a control group （n = 57） according to whether oral metoprolol succinate sustained release tablets were postoperatively administered. The patients with underlying diseases including hypertension， coronary heart disease， or diabetes were treated with antihypertensive drugs， hypoglycemic drugs， or anti-platelet aggregation drugs. The study group received oral metoprolol succinate sustained release tablets within one to three days after implantation of a leadless pacemaker； while the control group received no metoprolol succinate sustained release tablets. Changes in ventricular pacing threshold and intracardiac electrical signal amplitude were observed in two groups one week， one month and three months after implantation. Results No serious complications occurred in the patients at the three time points after implantation. Ventricular pacing thresholds were stable in both groups， and there was no statistical significance between the two groups as compared with the same time period （P > 0.05）. In terms of amplitude of ventricular intracardiac electrical signal， theamplitude of ventricular R-wave did not differ significantly between the two groups at the three time points after implantation（P > 0.05）. Conclusions Oral administration of metoprolol succinate sustained release tablets had no significant effects on acute phase ventricular pacing threshold and intracardiac electrical signal amplitude in a leadless pacemaker （Micra）.

Key words： leadless pacemaker; metoprolol succinate; pacing threshold; intracardiac electrical signal

Cite this article

Kaidi JING , Cheng LI , Xiao MA , Shubin JIANG , Lan. LI . Effects of metoprolol succinate on acute stage pacing threshold and amplitude of intracardiac electrical signal in a leadless pacemaker[J]. The Journal of Practical Medicine, 2024 , 40(21) : 3036 -3039 . DOI: 10.3969/j.issn.1006-5725.2024.21.012

References

1 HAI J， CHAN Y， LAU C， et al. Single‐chamber leadless pacemaker for atrial synchronous or ventricular pacing［J］. Pacing Clin Electrophysiol， 2020， 43（12）： 1438-1450. doi:10.1111/pace.14105
2 EL-CHAMI M F， BOCKSTEDT L， LONGACRE C， et al. Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study： 2-year follow-up［J］. Eur Heart J， 2022， 43（12）： 1207-1215. doi:10.1093/eurheartj/ehab767
3 BREEMAN K T N， KNOPS R E， TJONG F V Y. Leadless pacing： Also an option for the young？［J］. J Cardiovasc Electrophysiol， 2023， 34（2）： 418-419. doi:10.1111/jce.15797
4 王小霞，黄巧，彭闵，等. 心血管疾病老年共病患者出院准备服务的应用效果［J］. 实用医学杂志，2023，39（22）：3005-3009. doi:10.3969/j.issn.1006-5725.2023.22.026
5 ESLER M， KJELDSEN S E， PATHAK A， et al. Diverse pharmacological properties， trial results， comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified［J］. Blood Press， 2022， 31（1）： 210-224. doi:10.1080/08037051.2022.2110858
6 VAN KLEEF L A， LU Z， IKRAM M A， et al. Liver stiffness not fatty liver disease is associated with atrial fibrillation： The Rotterdam study［J］. J Hepatol， 2022， 77（4）： 931-938. doi:10.1016/j.jhep.2022.05.030
7 MOTAWEA K R， GABER H， SINGH R B， et al. Effect of early metoprolol before PCI in ST‐segment elevation myocardial infarction on infarct size and left ventricular ejection fraction. A systematic review and meta‐analysis of clinical trials［J］. Clin Cardiol， 2022， 45（10）： 1011-1028. doi:10.1002/clc.23894
8 姜述斌，李春山，帕尔哈提，等. 美托洛尔对安装永久心脏起搏器患者的心房和心室起搏阈值与心脏内电信号波幅的影响［J］. 中国介入心脏病学杂志，2008，16（4）：222-224.
9 BENCARDINO Gi， SCACCIAVILLANI R， NARDUCCI M L. Leadless pacemaker technology： clinical evidence of new paradigm of pacing［J］. Rev Cardiovasc Med， 2022， 23（2）： 43. doi:10.31083/j.rcm2302043
10 张广杰，崔丽君，达虹康，等. 双腔与单腔心脏起搏器在老年缓慢性心律失常患者中应用对比［J］. 世界复合医学，2023，9（8）：106-109.
11 陆政德，石磊，覃绍明，等. Micra 无导线起搏器和传统起搏器的近期临床疗效比较［J］. 中国心脏起搏与心电生理杂志，2022，36（1）：22-25.
12 NGO L， NOUR D， DENMAN R A， et al. Safety and Efficacy of Leadless Pacemakers： A Systematic Review and Meta-Analysis［J］. J Am Heart Assoc， 2021， 10（13）： e019212. doi:10.1161/jaha.120.019212
13 CURNIS A， SALGHETTI F， CERINI M， et al. Leadless pacemaker： State of the art and incoming developments to broaden indications［J］. Pacing Clin Electrophysiol， 2020， 43（12）： 1428-1437. doi:10.1111/pace.14097
14 GILL J. Emerging Technologies in Electrophysiology： From Single-Chamber to Biventricular Leadless Pacemakers［J］. Cardiology， 2022， 147（2）： 179-190. doi:10.1159/000521976
15 SPERZEL J， HAMM C， HAIN A. Nanostim-leadless pacemaker［J］. Herzschrittmacherther Elektrophysiol， 2018， 29（4）： 327-333. doi:10.1007/s00399-018-0598-3
16 ROBERTS P R， CLéMENTY N， MONDOLY P， et al. A leadless pacemaker in the real-world setting： Patient profile and performance over time［J］. J Arrhythm， 2023， 39（1）： 1-9. doi:10.1002/joa3.12811
17 EL‐CHAMI M F， BHATIA N K， MERCHANT F M. Atrio‐ventricular synchronous pacing with a single chamber leadless pacemaker： Programming and trouble shooting for common clinical scenarios［J］. J Cardiovasc Electrophysiol， 2021， 32（2）： 533-539. doi:10.1111/jce.14807
18 LI K， LIU J. Implantation of a leadless atrioventricular synchronous pacemaker Micra AV： A case report［J］. Asian J Surg， 2023，46（12）：5761-5762. doi:10.1016/j.asjsur.2023.08.133
19 MITACCHIONE G， SCHIAVONE M， GASPERETTI A， et al. Atrioventricular synchronous leadless pacemaker： state of art and broadened indications［J］. Rev Cardiovasc Med， 2021， 22（2）： 395-401. doi:10.31083/j.rcm2202045
20 何义，李岚，王潇，等. 稳心颗粒对急性期心房心室主动螺旋电极起搏阈值和心电信号振幅的影响［J］. 新疆医科大学学报，2021，44（11）：1250-1254.
21 祁杰，朱火兰，闫莉，等. 心脏永久性起搏器术后起搏阈值升高的临床相关影响因素分析［J］. 临床医学研究与实践，2017，2（28）：59-60.
22 无导线起搏器临床应用中国专家共识（2022）［J］. 中华心律失常学杂志， 2022，26（3）： 263-271.
23 MORITA J， KONDO Y， OKADA T， et al. Predictors of Pacing Capture Threshold Exacerbation After Leadless Pacemaker Implantation［J］. Int Heart J， 2023， 64（4）： 602-605. doi:10.1536/ihj.22-698
24 李健，杨立明. 永久性心脏起搏器植入术后起搏阈值升高的影响因素分析［J］. 中国民康医学，2021，33（17）：99-101. doi:10.3969/j.issn.1672-0369.2021.17.043
25 HILLMANN H A K， BETZ K， LINZ D， et al. How to： clinical use of antiarrhythmic drugs［J］. Herzschrittmacherther Elektrophysiol， 2023， 34（1）： 82-90. doi:10.1007/s00399-022-00919-y
26 余丽瑞，张敏. 心脏起搏阈值的影响因素［J］. 中国心脏起搏与心电生理杂志，2023，37（2）：150-153.
27 杨艳，马艳，林丽霞，等. 永久性心脏起搏器置入术后起搏阈值升高患者的临床特点及其相关影响因素分析［J］. 临床和实验医学杂志，2018，17（10）：1088-1091. doi:10.3969/j.issn.1671-4695.2018.10.027
28 LEI M， WU L， TERRAR D A， et al. Modernized Classification of Cardiac Antiarrhythmic Drugs［J］. Circulation， 2018， 138（17）： 1879-1896. doi:10.1161/circulationaha.118.035455
29 GRANDI E， RIPPLINGER C M. Antiarrhythmic mechanisms of beta blocker therapy［J］. Pharmacol Res， 2019， 146： 104274. doi:10.1016/j.phrs.2019.104274
30 HUANG C L H， WU L， JEEVARATNAM K， et al. Update on antiarrhythmic drug pharmacology［J］. J Cardiovasc Electrophysiol， 2020， 31（2）： 579-592. doi:10.1111/jce.14347
Options
Outlines

/

〈 〉